1. OPENING SESSION
(2010-04-28, 14:00:00 - 14:25:00)
Noncommunicable diseases: A major challenge to global development
(A. Alwan)
2. TOBACCO CONTROL
(2010-04-28, 14:25:00 - 15:00:00)
Tobacco Control- What is important for oncologists to know
(C. Dresler)
3. STAGE IIIA N2 NSCLC
(2010-04-28, 15:30:00 - 17:00:00)
Surgery still has a role to play in stage III NSCLC
(P. De Leyn)
Surgery still has a role to play in stage III NSCLC
(K. Albain)
Surgery has no role to play in stage III NSCLC
(B. Putnam)
Surgery has no role to play in stage III (N2) NSCLC
(J. Jassem)
4. IMPLICATIONS OF THE NEW STAGING SYSTEM – CASE-BASED
(2010-04-28, 17:00:00 - 18:00:00)
How should we use T?
(R. Rami-Porta)
Multiple nodules in the lungs
(P. Postmus)
The application of the new IASLC staging system to small cell lung cancer
(F. Shepherd)
Consequences of the new staging system
(J. Sculier)
5. THE EMERGING ROLE OF IMMUNOTHERAPY IN LUNG CANCER
(2010-04-28, 17:00:00 - 17:50:00)
The emerging role of immunotherapy in lung cancer
(J. Vansteenkiste)
6. RESTAGING TECHNIQUES
(2010-04-28, 17:00:00 - 17:50:00)
Restaging techniques
(P. E. Van Schil)
7. THE MANAGEMENT OF PLEURAL EFFUSION
(2010-04-28, 17:00:00 - 17:50:00)
The management of pleural effusion
(G. Rocco)
8. CHEMOTHERAPY FOR THE ELDERLY
(2010-04-29, 08:00:00 - 08:50:00)
Chemotherapy for the elderly
(E. Quoix)
9. THYMOMAS
(2010-04-29, 08:00:00 - 08:50:00)
Thymomas
(N. Girard)
10. IMPROVING SURVIVAL IN LS-SCLC AND ES-SCLC WITH RADIOTHERAPY
(2010-04-29, 08:00:00 - 08:50:00)
Improving survival in LS-SCLC and ES-SCLC with radiotherapy
(C. Faivre-Finn)
11. CIRCULATING LUNG CANCER CELLS
(2010-04-29, 08:00:00 - 08:50:00)
Circulating lung cancer cells
(J. Mazières)
12. EARLY NSCLC STAGE I/II: STATE-OF-THE-ART
(2010-04-29, 09:00:00 - 10:30:00)
How to manage stage I disease
(P. Van Houtte)
How important is lymph node dissection in stage I and II?
(P. De Leyn)
Neoadjuvant versus adjuvant chemotherapy
(E. Felip)
Fitness for radical treatment (ERS-ESTS guidelines)
(A. Charloux)
13. EARLY NSCLC INVITED PAPERS
(2010-04-29, 11:00:00 - 12:30:00)
Biological markers for selecting patients for chemotherapy
(M. G. Kris)
How far can we minimise surgery for stage I?
(H. Asamura)
Stereotactic radiotherapy: The new standard?
(B. J. Slotman)
How close are we to customizing chemotherapy in early NSCLC?
(J. Souglakos)
14. PATHOLOGY, BIOLOGY AND TRANSLATIONAL RESEARCH
(2010-04-29, 11:00:00 - 12:30:00)
Molecular and proteomic analyses of serum
(P. C. Mack)
15. SUPPORTIVE AND PALLIATIVE CARE
(2010-04-29, 14:20:00 - 15:50:00)
Supportive treatment: antiemetics and neutropenia
(M. S. Aapro)
How to manage the side-effects of chemotherapy
(T. Morán)
How to manage the side-effects of radiation
(M. Werner-Wasik)
16. MOLECULAR BIOLOGY
(2010-04-29, 14:20:00 - 15:50:00)
Discovering new mutations in lung cancer and new targeted therapies
(F. Ciardiello)
The biological significance of targeted therapies, including the mTOR pathway
(F. Khuri)
Randomized trials in patients with EGFR mutations
(T. Mok)
17. EARLY NSCLC CONTROVERSIAL ISSUES
(2010-04-29, 14:20:00 - 15:50:00)
New trials in early disease comparing surgery and radiation
(F. J. Lagerwaard)
Solitary pulmonary nodules: Diagnosis and management
(F. Herth)
Prognostic and predictive markers for selecting patients
(M. Taron)
18. RADIATION
(2010-04-29, 16:10:00 - 17:40:00)
The question of volume
(L. Gaspar)
The question of dose
(H. Choy)
The question of fractionation
(D. Ball)
IMRT versus 3DCRT for locally advanced Non-Small Cell Lung Cancer treated with concurrent chemotherapy
(R. Komaki)
19. EARLY NSCLC
(2010-04-29, 16:10:00 - 17:40:00)
Prevalence, correlations, and prognostic significance of the presence of microscopic vascular invasion following complete resection of Stage I non-small cell lung carcinoma. An underestimated factor?
(E. Ruffini)
Radiological and clinical pneumonitis after stereotactic lung radiotherapy: A matched comparison of 3D-conformal and volumetric modulated arc therapy techniques
(D. Palma)
Treatment utilization and survival for elderly patients with Stage I NSCLC: A population-based time-trend analysis
(D. Palma)
20. BIOLOGY
(2010-04-29, 16:10:00 - 17:40:00)
Reliable classification of non-small cell lung carcinoma using a novel microRNA-based approach
(W. H. Westra)
21. THE NEW ERS/IASLC/ATS CLASSIFICATION OF LUNG ADENOCARCINOMA
(2010-04-29, 17:45:00 - 18:45:00)
Surgery
(P. E. Van Schil)
22. IMAGING: STATE-OF-THE-ART
(2010-04-29, 17:45:00 - 18:45:00)
How to measure T status, different imaging techniques, different imaging methods
(W. De Wever)
New non-invasive imaging techniques in lung cancer (excluding PET)
(O. Lucidarme)
How should PET–CT influence our decision making?
(J. Vansteenkiste)
23. MESOTHELIOMA
(2010-04-29, 17:45:00 - 18:45:00)
Surgery for MPM; extrapleural pneumonectomy (EPP) vs. pleurectomy/decortication (P/D)
(M. Tsuboi)
Radiation
(C. Le Pechoux)
Systemic treatment and molecular pathways
(R. A. Stahel)
24. SCREENING
(2010-04-29, 17:45:00 - 18:45:00)
Spiral CT
(R. J. van Klaveren)
Do we need to screen persons exposed to asbestos?
(N. van Zandwijk)
Molecular screening
(C. Mascaux)
25. SCLC: DRUGS AND TARGETED THERAPIES
(2010-04-30, 08:00:00 - 08:50:00)
SCLC: Drugs and targeted therapies
(P. Baas)
26. THE MANAGEMENT OF BRAIN METASTASES
(2010-04-30, 08:00:00 - 08:50:00)
The management of brain metastases
(R. Mirimanoff)
27. THE NEW FRONTIERS IN SURGERY IN T4 TUMORS AND METASTATIC DISEASE
(2010-04-30, 08:00:00 - 08:50:00)
The new frontiers in surgery in T4 tumors and metastatic disease, including superior sulcus
(D. Grunenwald)
28. STAGE III NSCLC: STATE-OF-THE-ART
(2010-04-30, 09:00:00 - 10:30:00)
Optimising the systemic therapies in a multimodal approach
(K. O'Byrne)
Which patients are candidates for surgery?
(W. Weder)
29. STAGE III NSCLC INVITED PAPERS
(2010-04-30, 11:00:00 - 12:30:00)
Induction treatment – chemotherapy or chemoradiation?
(J. van Meerbeeck)
The morbidity of surgery after induction treatment
(A. J. Torres)
Optimal treatment for PS2 patients
(W. J. Curran)
30. TRANSLATIONAL RESEARCH
(2010-04-30, 11:00:00 - 12:30:00)
Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
(M. Reck)
Expression of VEGF ligands and receptors in tumor versus stromal cells in NSCLC: prognostic value
(E. Jantus Lewintre)
Increased thymidylate synthase (TS) gene copy number in NSCLC.
(M. W. Wynes)
Detection of Circulating Tumour Cells (CTCs) in Non-Small Cell Lung Cancer (NSCLC) by CellSearch and ISET Technologies
(M. Krebs)
31. METASTATIC NSCLC: STATE-OF-THE-ART
(2010-04-30, 14:20:00 - 15:50:00)
Oligometastases: The point of view of the radiologist
(H. Choy)
The role of first-line targeted therapies
(C. Gridelli)
Customizing systemic therapy in patients with advanced lung cancer
(P. R. Germonpré)
Maintenance therapy
(S. Novello)
32. COMBINED MODALITY THERAPY
(2010-04-30, 14:20:00 - 15:50:00)
Correlation of Imaging and histopathology in cold spots on FDG PET scans of non small-cell lung cancer (NSCLC) patients
(C. Siedschlag)
Induction Chemotherapy (I-CT) with Vinorelbine and Cisplatin followed by Concurrent Chemotherapy (CT-RT) and Dynamic Accelerated Hyperfractionated Radiotherapy (DAHR) (Zamora-Mitsoura regimen) in locally advanced Non-Small Cell Lung Cancer (NSCLC).
(J. Zamora-Moreno-Varaona)
Synchronous Brain Metastases from Non-Small Cell Lung Cancer: Time for Reappraisal of Extracranial Treatment Options?
(J. S. Lind)
33. METASTATIC NSCLC, BIOLOGY FROM THE BENCHMARK TO BEDSIDE INVITED PAPERS
(2010-04-30, 16:10:00 - 17:40:00)
The role of anti-angiogenic agents (TKIs)
(M. Reck)
Predictive markers of tumor response
(B. Besse)
Moving forward in the field of new oral inhibitors
(F. Cappuzzo)
34. TECHNICAL ASPECTS OF RADIOTHERAPY
(2010-04-30, 16:10:00 - 17:40:00)
Accelerated or hyperfractionated radiotherapy (RT) versus conventional RT in non metastatic lung cancer (LC): individual patient data (IPD) meta-analysis from 2279 patients (pts)
(C. Le Pechoux)
A 4D software for breathing adapted radiotherapy (BART) of lung cancer
(N. Peguret)
An analysis of Patients with brain metastases from Non small cell Lung Cancer treated with Short Course Accelerated Radiotherapy (SCAR)
(A. Munshi)
35. SURGERY
(2010-04-30, 16:10:00 - 17:40:00)
Pneumonectomy for lung cancer in non-academic community practice: quality recommendations from a large U.S. metropolitan area.
(M. Ninan)
PET-CT does not improve the outcome of lung cancer surgery
(K. K. Lau)
Prognostic Factors of Disease Recurrence and Overall Survival in Elderly Versus Young Patients in Surgically Resected Non Small Cell Lung Cancer
(B. Al-Alao)
Postoperative complications after lung cancer surgery in elderly patients: surgical procedures and risks.
(S. Shiono)
36. ADVANCED NSCLC
(2010-04-30, 17:40:00 - 19:20:00)
EGFR mutation testing in non-small-cell lung cancer (NSCLC): clinical recommendations from the European EGFR workshop group
(R. Pirker)
Different KRAS mutations may predict a different impact on drugs activity in lung (NSCLC) cancer.
(M. C. Garassino)
Survival benefit with erlotinib (Tarceva®) maintenance therapy relative to prior chemotherapeutic response: a subanalysis of the phase III SATURN study in NSCLC
(B. Coudert)
Quality of life (QoL) in a randomized phase III first-line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS)
(S. Thongprasert)
Efficacy and safety of doublet compared to single agent in advanced non small cell lung cancer. A systematic review and meta-analysis.
(G. Des Guetz)
Discussant
(E. Felip)
37. IMAGING
(2010-04-30, 17:40:00 - 19:10:00)
An Investigation of Metabolic Differences in Various Histological Types of Lung Cancer and the Potential Implications on Treatment and Prognosis.
(J. Singh)
Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS)
(P. Kumar)
Early Response Monitoring of Erlotinib and Sorafenib by 18F-Fluorodeoxygluose and 15O-Water Positron Emission Tomography in Non-Small Cell Lung Cancer
(J. S. Lind)
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method to monitor treatment: a new method to monitor treatment?
(J. S. Lind)
Early predictive value post chemotherapy of metabolic response assessment using Fluordeoxyglucose Positron Emission Tomography (FDG-PET) in Non Small Cell Lung Cancer
(T. Meniawy)
38. MESOTHELIOMA AND SCLC
(2010-04-30, 17:40:00 - 19:10:00)
Is there a role for high dose hemithoracic radiotherapy in unpneumonectomised mesothelioma patients?
(M. Feigen)
A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM)
(A. Bramati)
Validation and comparison of published prognostic classifications for survival in patients (pts) with small cell lung cancer (SCLC)
(M. N. Paesmans)
Outcome of prophylactic cranial radiotherapy in extensive-stage small cell lung cancer: The Christie experience over two years
(N. Ghosal)
Standardized Uptake Values of Positron Emission Tomography/Computed Tomography (PET/CT) as Malignant Predictor in Thymoma
(L. Bertolaccini)
39. SAFETY AND TOXICITY
(2010-04-30, 17:40:00 - 19:10:00)
Risk factors for early complications of high dose rate endobronchial brachytherapy (HDR EBBT) in the palliative treatment of lung cancer.
(B. Zaric)
MO19390 (SAiL): final safety and efficacy data for first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)
(P. Garrido Lopez)
Safety of bevacizumab (Bv)-based therapy as first-line treatment of elderly patients (pts) with advanced non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)
(M. Reck)
Final safety data for Chinese patients (pts) with non-squamous non-small cell lung cancer (NSCLC) who received first-line bevacizumab (Bv) plus chemotherapy in SAiL (MO10390)
(Y. Wu)
Risk of Severe Pulmonary Hemorrhage (sPH) Associated with Development of Cavitation while on Bevacizumab (BV) Therapy in Patients (pts) with Non Small Cell Lung Cancer (NSCLC): Results from ARIES, a BV Treatment Observational Cohort Study (OCS)
(D. R. Spigel)
40. PREVENTION, LOCALLY ADVANCED AND EARLY NSCLC
(2010-05-01, 08:00:00 - 08:50:00)
Discussant
(E. Quoix)
Discussant
(W. Eberhardt)
41. ADVANCED NSCLC
(2010-05-01, 08:00:00 - 08:50:00)
Discussant
(M. Reck)
Discussant
(V. Westeel)
42. TRANSLATIONAL RESEARCH AND BIOLOGY
(2010-05-01, 08:00:00 - 08:50:00)
Discussant
(J. Wei)
Discussant
(F. Blackhall)
43. FUTURE DIRECTIONS IN THE TREATMENT OF NSCLC
(2010-05-01, 09:00:00 - 09:30:00)
Future directions in the treatment of NSCLC
(P. A. Bunn, Jr.)
44. CONTROVERSY SESSION - STAGE III: COMBINED TREATMENT
(2010-05-01, 09:30:00 - 10:20:00)
Stage III: Combined treatment - Sequential
(R. Dziadziuszko)
Stage III: Combined treatment - Concurrent
(D. De Ruysscher)
45. CONTROVERSY SESSION - STAGE IV: TARGETED THERAPY AS FIRST LINE TREATMENT
(2010-05-01, 10:40:00 - 11:30:00)
Stage IV: Targeted therapy as first line treatment - Yes
(R. Pirker)
Stage IV: Targeted therapy as first line treatment - No
(G. V. Scagliotti)
46. GRAND ROUND
(2010-05-01, 11:30:00 - 12:45:00)
Stage III NSCLC
(P. Van Houtte)
 

© 2010, ELCC
To display the content of the website correctly you need Flash Player 8 for Windows or Flash Player 7 for MacOS. Download the newest version and install it, this requires only a few minutes.